Hospitals’ next cyber risk? The fridge.

By CLAUDIA CHIAPPA with DOMINIC GIANNINI and EMMA PIRNAY SNEAK PEEK The cyber resilience of Europe’s health systems is under the spotlight after an attack on French refrigerators raises concern about vaccine vulnerabilities. Health payers and patient groups want a new EU-funded tool to ensure innovative medicines remain affordable amid U.S. pricing pressures. The European […]

Read More

A ‘fridge-free vaccine’ has the potential to transform African immunisation

Read original article on New African UK-based pharmaceutical company Stablepharma is preparing for a pivotal Phase 2b clinical trial of ‘SPVX02’, its thermostable version of an existing tetanus-diphtheria vaccine, following the success of a Phase 1 clinical trial. Unlike conventional vaccines which become unusable after a few hours or days out of the fridge, ‘SPVX02’ […]

Read More

“Fridge-free” vaccine for tetanus-diphtheria shows promise in first human trial

Read original article on BMJ.com A tetanus-diphtheria vaccine that can be stored at room temperature has shown promising early results in a development hailed as a potential “game changer” for global health. Maintaining the cold chain for vaccines is a significant challenge in resource poor countries, remote communities, and regions affected by conflict. About half […]

Read More

Half of vaccines are binned – ‘fridge-free’ versions could change that

Read original article on bbc.co.uk Vaccines that do not need to be kept cool in a fridge have been successfully trialled in patients for the first time, say UK scientists. Currently, most vaccines need to be refrigerated or frozen – but around half are wasted each year, mainly because they become unusable after getting too […]

Read More

Stablepharma enters Phase 1 Clinical Trials with world-first Fridge-Free Td Vaccine

Following MHRA approval, Stablepharma Ltd has commenced a Phase 1 clinical trial with its lead candidate, fridge-free tetanus and diphtheria vaccine, SPVX02. The Phase 1, first-in-human clinical trial led by Professor Saul Faust, is being conducted at the National Institute for Health and Care Research (NIHR) at Southampton Clinical Research Facility. Stablepharma’s pioneering science has […]

Read More